Brazil temporarily halted administration of its single-dose dengue vaccine on the date of 2026-06-08 after authorities identified two deaths and one other severe case among people who had received the shot, according to AFP reporting carried by The Straits Times.
Health Minister Alexandre Padilha said officials did not have enough evidence to conclude that the vaccine caused the three serious outcomes. He described the cases as a safety warning that justified a precautionary pause while they were examined.
The vaccine was developed publicly in Brazil and had been approved by the country’s health authorities in November. It is described as the world’s first single-dose vaccine against dengue, a mosquito-borne viral disease that can produce high fever, headaches, muscle pain, nausea and rashes. In uncommon cases, dengue can be fatal.
More than 501,000 people received the vaccine between January and May 2026. The health ministry said 3,703 recipients, or 0.7 percent, developed symptoms resembling dengue. Forty-two people were reported to have had more severe reactions, while authorities highlighted three severe cases for closer scrutiny: a 58-year-old man and a 48-year-old woman who died, and a 38-year-old woman who was admitted to intensive care and later discharged.
Padilha said the effects under review had not appeared in testing involving more than 16,000 volunteers across 14 Brazilian states. Those trials recorded an efficacy rate of 91.6 percent against the most severe form of dengue, according to the account.
The suspension leaves unanswered when, or under what conditions, the vaccination campaign might resume. AFP reported that the minister did not specify what evidence or regulatory steps would be required before the vaccine could be reintroduced.
The development is significant because a one-dose formulation could make dengue immunisation campaigns easier to organise than products requiring multiple appointments. The World Health Organization identifies TAK-003 as another dengue vaccine that is given in two doses three months apart, according to the report.
Dengue has been a major public health problem in Brazil. The country recorded more than 6,000 dengue deaths in 2024, nearly half of deaths reported worldwide that year, before conditions improved markedly in 2025.
The ministry’s action does not establish that vaccination caused the deaths or the intensive-care case. Rather, officials framed the decision as a temporary precaution after rare but serious reports emerged in a rollout that had already reached more than half a million people. Further findings from Brazil’s safety review will be central to whether confidence in the single-dose product can be restored and whether its expected logistical advantages can be used in future dengue control efforts.
